Nektar signs up on record-breaking collaboration deal

14 February 2018
2019_biotech_test_vial_discovery_big

Rather surprisingly, US biotech firm Nektar Therapeutics (Nasdaq: NKTR) was trading down 4.32% at $72.39 pre-market this morning, even though news had broken that it has entered into a collaboration which, including an equity investment, could be worth a record-breaking $3.6 billion. However, after the market opened, the stock started moving up around 8% to $81.74 by mid-morning.

Nektar has executed a global strategic development and commercialization collaboration with pharma major Bristol-Myers Squibb (NYSE: BMY) for its lead immuno-oncology program, NKTR-214, as B-MS searches for a competitive edge over Keytruda (pembrolizumab) and other rival checkpoint inhibitors.

Under the collaboration, the companies will jointly develop and commercialize NKTR-214 in combination with B-MS’ Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in more than 20 indications across nine tumor types, as well as potential combinations with other anti-cancer agents from either of the respective companies and/or third parties.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology